|
Synonyms: example 63 [WO2019149738A1] | HRX-0215 | HRX-215 | HRX215
Compound class:
Synthetic organic
Comment: This is the chemical structure for the INN darizmetinib. This structure is claimed in HepaRegeniX's patent WO2019149738A1, as a mitogen-activated protein kinase kinase 4 (MKK4) inhibitor [3]. The association of darizmetinib with HepaRegeniX's lead MKK4 inhibitor HRX215 was disclosed in May 2026 [1]. MKK4 is a key regulator of liver regeneration that operates predominantly via MKK7 and JNK1. Inhibition of MKK4 accelerates and enhances the liver's natural regenerative capacity [4].
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
|||||||||||||||||||||||||||||||||||
| No information available. |
Summary of Clinical Use ![]() |
| The MKK4 inhibitor HRX215 was progressed to phase 1, first-in-human evaluation in August 2021. It was subsequently evaluated for efficacy as a treatment for acute and chronic liver diseases. In September 2026 the US FDA granted orphan drug status, for the prevention of post‑hepatectomy liver failure [2]. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT06638502 | Safety of HRX215 in Patients After Minor and Major Liver Resection | Phase 1/Phase 2 Interventional | HepaRegeniX GmbH | ||
| NCT07612007 | HRX215, A First Generation MKK4 Inhibitor Drug, for the Treatment of Patients With Colorectal Liver Metastasis After Undergoing a Portal Vein Embolization | Phase 2 Interventional | Mayo Clinic | ||